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A B S T R A C T
Objective: Utility-based measures of quality of life are recommended by some decision
makers in health care. No studies have addressed changes in utility in patients with chronic
idiopathic thrombocytopenia (ITP). This study sought to assess the health utilities of pa-
tients with chronic ITP and to evaluate the association of change in health utility with
changes in other variables, including platelet response status and bleeding events.
Methods: We analyzed EQ-5D data from two international, randomized, placebo-con-
trolled, double-blind, 24-week trials that evaluated the efficacy and safety of romiplostim in
adult patients with chronic ITP.
Results: A total of 125 subjects participated. Mean change, adjusted for age, gender, splenec-
tomy status, and baseline score using multiple linear regression models was greater for romi-
plostim versus placebo for the EQ-5D index score (0.05 vs. 0.03, P  0.015) and the VAS score
(6.42 vs. 0.48, P  0.066); similar for durable platelet responders versus nonresponders; and
greater for EQ-5D index scores for subjects who did not have a bleeding event during the study
(n 29) compared to subjects who did have a bleeding event (n 47) (0.06 vs. 0.005; P 0.066).
Conclusions: Using romiplostim in cases of chronic ITP was associated with improvement in
health-relatedqualityof life asmeasuredby theEQ-5D indexscore.Healthutility scoresderived
using the EQ-5D in this studymay be useful for determining quality-adjusted life years (QALYs)
in economic evaluations of romiplostim for treatment of chronic ITP.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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91V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 – 9 6ealth-related quality of life (HRQoL) for that particular health
tate. Most HTA organizations align with decision makers such
s theNational Institute forHealthandClinical Excellence (NICE)
n the United Kingdom, asserting that values for health states
hould reflect thoseof the general public using standardizedval-
dated generic instruments with preference-based methods [1].
nterventions can then be evaluated in different disease areas
sing a standard scale.
No studies have assessed the change in health utility in pa-
ients with chronic immune thrombocytopenia (ITP). There are
nly a few generic preference-based instruments available that
re capable of detecting changes in health states, including the
Q-5D [2], the Health Utilities Index [3], and the SF-6D [4]. The
Q-5D and SF-6D recently have been compared side-by-side in
everal studies [5–7]. Although there are some conflicting re-
ults, both instruments have been shown to be capable of de-
ecting some degree of change in several disease settings. The
Q-5D has a number of country-specific choice-based prefer-
nceweights available [8], whereas the SF-6D is limited to only
he United Kingdom. Therefore, as a first step in understand-
ng preference-based health utility in chronic ITP, we chose
he EQ-5D to be administered as part of a multinational, ran-
omized, placebo-controlled trial.
ITP is an immune-mediated disease characterized by in-
reased platelet destruction and thrombocytopenia [9]. Pri-
ary ITP is defined by a peripheral blood platelet count
100  109/L, in the absence of other causes or disorders that
ay be associated with thrombocytopenia. ITP may be newly
iagnosed (within 3months of diagnosis), persistent (lasting 3
o 12months from diagnosis), or chronic (lastingmore than 12
onths) [10]. The incidence of ITP has been estimated to be
bout 100 cases per million persons per year, including both
dults and children [11,12]. First-line treatment for ITP con-
ists primarily of corticosteroids, with response rates between
0% and 75% [11]. The goal of treatment is to provide a safe
latelet count that will prevent major bleeding. Most fatal
leeding events have been reported in adults with ITP with
latelet counts below 30  109/L, but treatment should also
ake into account patient age and severity of ITP [10]. Bleeding
vents are costly, leading to hospitalizations which are likely
o be the major cost factor in patients with chronic ITP. The
isk of hemorrhage can be as high as 13% per year in older,
reatment-refractory patients [12]. Patients who are not re-
ponsive to corticosteroids and those who relapse are often
reated with intravenous immunoglobulin (IVIg), anti-D anti-
odies, or, alternatively, anti-CD20 antibodies [13]. Romiplos-
im, a novel thrombopoiesis-stimulating protein, has been
hown to result in statistically significant improvements—
rom 38% (splenectomized patients) to 56% (nonsplenecto-
ized patients) in durable platelet response compared to pla-
ebo, with minimal side effects [14]. If medical treatment is
ot successful, then splenectomy is considered [13].
Several recent studies have shown that individuals with
TP have symptoms as well as deficits in their daily activities
hat significantly impact their HRQoL [15–17]. The objectives
f this study were to assess the health utilities of chronic ITP
atients and to evaluate the association of change in health
tility scores with other variables, including platelet response
tatus and bleeding events. sethods
tudy population
atients enrolled in one of two multicenter, randomized (2:1
atio for romiplostim vs. placebo), placebo-controlled, double-
lind trials conducted at 35 centers in the United States, the
nited Kingdom, France, The Netherlands, and Spain were
sked to complete the EQ-5D at baseline (week 1) andweeks 5,
3, and 25. Both studies were designed to evaluate the efficacy
nd safety of romiplostim in adult patients with chronic ITP.
owever, one study enrolled patients with chronic ITP who
ad undergone splenectomy; the other included only non-
plenectomized patients who received at least one prior treat-
ent for ITP. Men or women aged 18 years or older with a
iagnosis of chronic ITP according to American Society of He-
atology guidelines [18] with a platelet count of 30  109/L
mean of three counts taken during the screening and pre-
reatment period) were eligible to participate. Patients older
han 60 years of age underwent bone marrow biopsy confir-
ation of their diagnosis of ITP. Patients received subcutane-
us injections of romiplostim (or placebo) once perweek start-
ng at a dose of 1 g/kg. Dose adjustment was permitted
hroughout the 24-week treatment period tomaintain platelet
ounts in the target range of 50 to 200  109/L [14].
Q-5D assessment
he EQ-5D is a brief, six-item, self-administered instrument
sed in a variety of health conditions and settings that allows
or easy administration and yields summary values that can
e readily incorporated into cost-utility studies [2]. The EQ-5D
easures HRQoL on five dimensions (mobility, self care, usual
ctivities, pain/discomfort, and anxiety/depression) and a
0-cm vertical visual analogue scale (VAS) that generates a
elf rating of HRQoL. Each of the five dimensions contains
hree levels. Respondents score each dimension, which re-
ults in a one-digit number that expresses the level selected
no problems, some problems, extreme problems) for that di-
ension. All five responses are then combined for a five-digit
ealth state, scored using an algorithm based on a sample from
he adult US population to generate preference weights for the
ealth state score [19]. The US-based scoring system was se-
ected because 83% of the study subjects resided in the US.
igher values for both the health state and VAS scores indicate
etter HRQoL. Change in the EQ-5D scores from baseline to the
ast visit (week 25) was a secondary end point in both clinical
rials. Patients self-administered the EQ-5D (prior to treatment
dministration or any clinical procedures) at baseline (week 1)
nd at weeks 5, 13, and 25 of the treatment period.
latelet response
n both clinical trials, patients who achieved a platelet count
f 50  109/L at any of the scheduled weekly clinic visits
ithout having used rescue medication within 8 weeks on or
rior to the visit were defined as having a weekly platelet re-
ponse. Durable platelet response was defined as having
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92 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 – 9 6eekly platelet responses for 6 weeks of the last 8 weeks of
reatment of the 24-week treatment period in the absence of
escuemedication.When platelet counts drop below 50 109/L,
atientsmay be at increased risk for bleeding [10]. To assess the
ssociation of improvement in health utility scores over the
ourse of the 24-week trial with the platelet response status, we
ompared the change in utility scores in responders versus non-
esponders. Differences in EQ-5D and VAS utility scores were
lso compared between platelet response groups at baseline
week 1) and weeks 5, 13, and 25 of the treatment period.
leeding-related episode
bleeding-related episode (BRE) was defined as the presence
f one or more bleeding events over the 24-week treatment
eriod that could be clinically assessed cumulatively in terms
f frequency, duration, and severity over the course of the
rial. Bleeding events were recorded with all adverse events
ollected in both trials and rated on a scale of 1 to 5 (1 mild,
moderate, 3  severe, 4  life threatening, and 5  fatal).
REs were identified by applying an algorithm that combines
oth bleeding and the use of rescue medication during the
reatment period. The algorithm included for key compo-
ents: duration between BREs, discernment of overlap in per-
istent BREs with that of new or more serious BREs, time on
tudy starting from the first treatment dose to the last treat-
ent dose received, and, finally, assignment of the nearest
latelet count to each BRE. Platelet counts were assigned to
REs in two ways: 1) platelet counts taken within one day of
he BRE, or 2) if the platelet count occurredmore than one day
efore or after the BRE, the closest platelet count (before or
fter the BRE) was estimated by linear interpolation for each
ay in that interval to arrive at an interpolated platelet count
or that day of the BRE.
tatistical methods
escriptive statistics were used to evaluate demographic and
aseline characteristics for all patients, including age, gender,
ace, number of years since ITP diagnosis, baseline platelet
ount, and EQ-5D scores. For categorical variables, the number
nd percentage are reported. Continuous variables are sum-
arized by n, mean, and standard deviation. Summary index
nd VAS scores for the EQ-5D were plotted for romiplostim
ersus placebo, responders versus nonresponders, and those
ith BREs versus those without BREs with 95% confidence in-
ervals at baseline (week 1) and weeks 5, 13, and 25. No impu-
ation of missing data was done, unless a patient died, in
hich case zero was imputed. Although the data were from
andomized trials, adjustmentsweremade for age and gender
o guard against potential imbalances that may be present
ith a relatively small sample size and to tease out potential
ge or gender effects on the EQ-5Dmeasures, if such effects do
xist. Multiple linear regression models were applied to esti-
ate the mean change from baseline to the last visit by treat-
ent group in responders versus nonresponders, and BRE
ersus non-BRE groups. In addition to age and gender, we ad-
usted for baseline EQ-5D scores and splenectomy status. We
lso fit repeatedmeasures regressionmodels with these score bhanges as the response variable and the main factor that we
re interested in (e.g., treatment) as the predictors along with
ovariates including splenectomy status, baseline EQ-5D
core, age group, and gender. P values of the type III tests for
he fixed effects of these factors are obtained to determine if
he main effect of interest is a significant factor. Similarly, the
epeated measures analyses with the other factors, responder
tatus and bleeding events, were carried out as well. However,
hese analyses were performed with the observations from the
omiplostim treatment group only (n 76), because the number
f responders in the placebo group was quite low (n  1, with a
efinition of50 109/L) and because of potential difficulties in
nterpreting results in bleeding events using data from both
reatment groups combined.
esults
total of 125 subjects (83 on romiplostim and 42 on placebo)
ook part in the studies. At baseline (week 1), 117 subjects
ompleted the EQ-5D, and only a small percentage of subjects
ad missing EQ-5D data at follow-up. Specifically, EQ-5D data
ere missing for two subjects at week 5, for one subject at
eek 13, and for one subject at week 25 (end of treatment).
As shown in Table 1, subjects on romiplostim and placebo
ad similar demographic and baseline clinical characteristics.
eanagewasearly tomid-50s.More thanhalf of the samplewas
emale (65%), and a majority of subjects (82%) were white. The
verage time since initial ITP diagnosis was approximately 8
ears, and the mean baseline platelet count was 16 109/L.
Ceiling effects were detected for the EQ-5D index score,
hereas floor effects were minimal. Overall, 2% of the EQ-5D
ndex scores were below 0, and 22% were equal to 1. At base-
ine, less than 1% of the EQ-5D index scores were below 0, and
3% were equal to 1. At week 25, about 1% of the EQ-5D index
coreswere below0, and 24%were equal to 1 (data not shown).
ests of heteroscedascity were not statistically significant.
Mean EQ-5D index scores and VAS scores by study week for
Table 1 – Demographic and clinical characteristics of
study population.
Romiplostim Placebo
Number of patients 83 42
Mean age (SD) 52 (15.5) 55 (17.8)
Female, n (%) 54 (65.1) 27 (64.3)
Race, n (%)
White 65 (78.3) 37 (88.1)
Black 6 (7.2) 3 (7.1)
Hispanic 6 (7.2) 2 (4.8)
Asian 5 (6.0) 0 (0.0)
Pacific Islander 1 (1.2) 0 (0.0)
Mean (SD) years since ITP
diagnosis
8 (10.6) 8 (7.9)
Mean (SD) baseline platelet
count (109/L)
16 (7.8) 17 (8.5)
Mean (SD) baseline EQ-5D
index score
0.8 (0.2) 0.7 (0.2)
Mean (SD) baseline EQ-5D
VAS score
67 (21.0) 61 (20.0)oth treatment groups are shown in Figure 1. Differences be-
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93V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 – 9 6ween EQ-5D index and VAS scores by treatment group differed
fair amount numerically at all study visits. In addition, the rate
f change in both EQ-5D index and VAS scores for patients on
omiplostim ishighest frombaseline toweek5and fromweek13
o week 25. Change from baseline to last visit for romiplostim
as 0.024 versus0.005 for placebo for the EQ-5D index and 7.42
ersus 1.82 for the VAS score (data not shown). Using multiple
inear regression analyses, adjusted mean change scores to the
ast visit were statistically significant for subjects on romiplos-
im versus placebo for the EQ-5D index score (0.05 vs.0.03, P
.015) and were numerically greater for the VAS score (6.42 vs.
.48, P 0.066) (Table 2). The greater change indicates that sub-
ects on romiplostim had greater improvements in health utility
han subjects on placebo. The repeatedmeasure analysis evalu-
ting the overall time variant of change score showed similar
esults for romiplostim vs placebo (P 0.071 for the EQ-5D index
core, P 0.010 for the EQ-5D VAS score).
Figure 2 displays mean EQ-5D index and VAS scores by
esponse status in terms of durable platelet count level. Re-
ponders and nonresponders differed numerically on the
Q-5D index andVAS scores atmost study visits. Change from
aseline to last visit for responders was 0.017 versus 0.013 for
onresponders for the EQ-5D index and 8.91 versus 3.77 for
he VAS score (data not shown).
Comparable repeated measures general linear models
ere used to evaluate the effect of response status and the
0.64 
0.68 
0.72 
0.76 
0.8 
0.84 
0.88 
0 5 10 
Av
er
ag
e 
EQ
-5
D
 In
de
x 
rom
50 
54 
58 
62 
66 
70 
74 
78 
82 
0 5 10 
Av
er
ag
e 
EQ
-5
D
 V
A
S 
romi
Fig. 1 – EQ-5D scores over stffect of bleeding status on EQ-5D mean change scores fromaseline using data for subjects on romiplostim only. Differ-
nces for responders versus nonresponders did not reach sta-
istical significance (Table 3).
For the analysis of bleeding status EQ-5D index and VAS
cores also differed by a fair amount numerically at each study
isit (Figure 3). Again the greatest increase for both index and
AS scores occurred between baseline andweek 5. Change from
aseline to last visit for thosewith a BREwas0.008 versus 0.070
or thosewithnoBRE for theEQ-5D indexand6.73versus 8.50 for
heVAS score (data not shown). Usingmultiple linear regression
nalyses, theadjustedmeanchange to the last visit on theEQ-5D
ndex score (Table 4) was numerically greater for subjects who
id not have a BRE at any point in the study (n 29) compared to
ubjects who did have a BRE (n  47) (0.06 vs. 0.005; P  0.066),
Table 2 – Mean change (SE) for EQ-5D scores to last visit
by treatment group*.
Romiplostim Placebo P value
EQ-5D index score n  76 n  41 0.015
0.05 (0.02) 0.03 (0.02)
EQ-5D VAS score n  73 n  41 0.066
6.42 (2.08) 0.48 (2.59)
* Mean change and P value were adjusted for baseline score, age
(40, 40–65, and 65), gender, and splenectomy status. Sample
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94 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 – 9 6ndicating a greater improvement for those who did not experi-
nce a bleeding event. In addition, the occurrence of a bleeding
vent had a numerical difference that did not achieve statistical
ignificance on the EQ-5D VAS score (6.19 vs. 3.07; P 0.453).
iscussion
hese results show that the use of romiplostim in patients
ith chronic ITP was associated with improvement in health
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Fig. 2 – EQ-5D scores over study
Table 3 – Mean change (SE) for EQ-5D scores to last visit
by durable response status defined as platelet level
>50x109/L for at least 6 weeks in last 8 weeks*.
Responders Nonresponders P value
EQ-5D index
score
n  37 n  39 0.834
0.03 (0.02) 0.03 (0.02)
EQ-5D VAS
score
n  36 n  37 0.190
7.61 (3.31) 2.05 (2.66)
* Mean change and P value were adjusted for baseline score, age
(40, 40–65, and 65), gender, and splenectomy status. Sample
sizes are based on nonmissing baselines for the romiplostim
treatment group only. Platelet counts within 8 weeks after rescuer
medication use were excluded.tility as measured by the EQ-5D index and VAS scores. This
nding suggests that the EQ-5D detected improvements in
ealth utility as patients’ platelet levels improved. For pa-
ients treated with romiplostim, the greatest rate of change in
oth EQ-5D index and VAS scores across the treatment period
s seen from baseline to week 5, likely because of the immedi-
te effect of treatment response during the first 4 weeks fol-
owed by a period of targeting the achievement of sustained
latelet response of 50  109/L. From weeks 5 to 13, patients
ay stabilize for a period of time as they grow accustomed to
iving without a constant fear of bleeding. Scores increase
nce again at week 25 in the romiplostim group.
In assessing change in utility scores over time it is impor-
ant to note that the mean weekly scores for the EQ-5D index
id not obtain statistical significance between treatment
roups at any given single assessment throughout the treat-
ent period. However, in the multiple regression analysis,
fter adjusting for potential confounding factors, the change
o the last visit in the romiplostim group was significantly
igher (better) than placebo for the EQ-5D index scores. With
he rate of increase at week 25 greater in the romiplostim
roup versus placebo, had the trial continued with longer fol-
ow-up it is possible that even greater differences between the
roups may have emerged.
No significant differences were detected in the analysis of
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95V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 – 9 6ach study assessment or for adjusted mean change scores to
he last visit. However, there was a trend toward greater im-
rovement in VAS scores in the responder group for the re-
eated measures analysis. To determine whether the results
ere dependent on our definition of responder, we repeated
he analysis using a definition of durable platelet response of
30 109/L. Patients with platelet counts below 30 109/L are
t greater risk for severe bleeding. [18,20] Again, no significant
ifferences were found between groups, although a similar
rend was seen toward greater improvement in VAS scores in
he responder group (6.84 vs. 1.99, P  0.095).
Clinically significant BREs are foremost in terms of risk to
atients with chronic ITP and may result in increased hospi-
alizations and risk of possible death. Patients with BREs had
lightly lower scores in the EQ-5D VAS (P  0.453) and moder-
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Fig. 3 – EQ-5D scores over s
Table 4 – Mean change (SE) for EQ-5D to last visit by
bleeding-related episode (BRE) status*.
Had BRE No BRE P value
EQ-5D index score n  47 n  29 0.066
0.005 (0.02) 0.06 (0.03)
EQ-5D VAS score n  46 n  27 0.453
3.07 (2.61) 6.19 (3.37)
* Mean change and P value were adjusted for baseline score, age
(40, 40–65, and 65), gender, and splenectomy status. Sample
sizes are based on nonmissing baselines for the romiplostimo
treatment group only.tely lower index scores (P  0.066) than patients who did not
xperience a BRE. In an analysis of a romiplostim open-label
tudy that recruited patients from this study, investigators
eported that bleeding events of grade 2 and higher were sig-
ificantly lower than during the 24-week treatment period of
he phase 3 trials of romiplostim compared to placebo [21].
here was no significant effect of when a BRE event occurred
n either the EQ-5D index or VAS scores over the 24-week
tudy period, suggesting that the timing of when the BREs
ccur does not impact patients’ HRQoL. Future research may
eek to determine whether the severity of BREs has an impact
n patients’ HRQoL.
Some limitations apply to our study. All bleeding analyses
ere performed as a post-hoc analysis and not prespecified
nd points in the phase 3 clinical trial. Also, due to the rarity of
hronic ITP, sample size was small and power calculations
ere driven by the primary clinical end points for the trials,
ot the secondary utility end points of the EQ-5D. A larger
ample size may have been able to detect more significant
ifferences. Finally, using generic preference-based instru-
ents may lack sensitivity in specific disease contexts. A
ore sensitive, disease-specific instrument may have greater
esponsiveness than the EQ-5D. Furthermore, there is evi-
ence of ceiling effects with the EQ-5D [22]. In this study, ceil-
ng effectswere present in nearly one-quarter of the sample at
aseline, allowing no room for improvement. An instrument
ith fewer ceiling effects may have resulted in greater mean
hanges from baseline. Further studies utilizing direct meth-
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96 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 – 9 6ble in comparing utilityweights derived in our study from the
Q-5D with that of a study with larger samples and the utility
eights derived as perceived by the general public [23].
The findings from this study provide evidence suggesting
hat the EQ-5D index score can discern statistically significant
ifferences in treatment groups in a placebo-controlled inter-
entional trial of romiplostim for treatment of chronic ITP.
hese results providepreliminaryfindingsasafirst step towards
nderstanding the validity and responsiveness of the EQ-5D in
he chronic ITP setting. Future studies comparing the respon-
iveness of the EQ-5D with other health utility instruments or
irectmethods such as time trade-off or standard gamblewould
e valuable and should be considered indefininghealth states in
hronic ITP. Utility scores from the EQ-5D may be useful as
eights for derivingQALYs for the economic evaluation of romi-
lostim for treatment of patients with chronic ITP.
onclusions
he EQ-5D was administered to chronic ITP patients enrolled in
ne of two multicenter, multinational clinical trials evaluating
heefficacyof romiplostimversusplacebo toderivehealthutility
eights andmeasure the association of change in health utility
ith change in platelet count. The use of romiplostim in chronic
TP was associated with statistically significant improvement in
RQoL, asmeasuredby theEQ-5D indexscores. Patientswhodid
ot experience a BRE had greater improvements in HRQoL, as
easured by the EQ-5D index scores.
The health utility scores derived using the EQ-5D in this
tudy provide weights that may be useful for determining
ALYs in economic evaluations of romiplostim for treatment
f chronic ITP in HTAs by decision-making authorities.
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